Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Michele Ghidini, Alice Indini, Olga Nigro, Simona Polito, Erika Rijavec, Fausto Petrelli & Gianluca Tomasello. (2021) Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opinion on Pharmacotherapy 22:7, pages 857-865.
Read now
Read now
Roberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, Donatella Telesca, Maria Rita Milella & Pellegrino Musto. (2016) Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics: Targets and Therapy 10, pages 1-8.
Read now
Read now
Margherita Ratti & Gianluca Tomasello. (2015) Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. Expert Review of Clinical Pharmacology 8:1, pages 15-24.
Read now
Read now
A. Engert, L. Griskevicius, Y. Zyuzgin, H. Lubenau & A. del Giglio. (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leukemia & Lymphoma 50:3, pages 374-379.
Read now
Read now
Mariko Morishita & Robert C Leonard. (2008) Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor–expanding uses in cancer chemotherapy. Expert Opinion on Biological Therapy 8:7, pages 993-1001.
Read now
Read now
Gary H Lyman. (2005) Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opinion on Biological Therapy 5:12, pages 1635-1646.
Read now
Read now
Articles from other publishers (31)
Genzhu Wang, Yonghe Zhang, Xiaoying Wang, Qiang Sun, Zhikun Xun, Minglu Yuan & Zhongdong Li. (2021) Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China. Medicine 100:51, pages e28218.
Crossref
Crossref
H. Xu, Q. Gong, F. D. Vogl, M. Reiner & J. H. Page. (2015) Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Supportive Care in Cancer 24:2, pages 723-730.
Crossref
Crossref
Edgar Petru, Christian F. Singer, Stephan Polterauer, Arik Galid, Christian Schauer, Johann Klocker, Michael Seifert, Alexander Reinthaller, Christoph Benedicic, Michael Hubalek, Lukas Hefler, Christian Marth, Tonja Scholl-Firon, Gerhard Bogner & Alain-Gustave Zeimet. (2015) Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statementProphylaxe mit langwirksamen Granulozyten-Kolonie-stimulierenden Faktoren (G-CSF) bei gynäkologischen Malignomen. Wiener Medizinische Wochenschrift 165:19-20, pages 387-394.
Crossref
Crossref
Sibylle Schirm, Christoph Engel, Markus Loeffler & Markus Scholz. (2014) Modelling chemotherapy effects on granulopoiesis. BMC Systems Biology 8:1.
Crossref
Crossref
S. Zeynalova, M. Ziepert, M. Scholz, S. Schirm, C. Zwick, M. Pfreundschuh & M. Loeffler. (2013) Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Annals of Hematology 92:12, pages 1641-1652.
Crossref
Crossref
Markus Scholz, Sibylle Schirm, Marcus Wetzler, Christoph Engel & Markus Loeffler. (2012) Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. Theoretical Biology and Medical Modelling 9:1.
Crossref
Crossref
C. Sebban, A. Lefranc, L. Perrier, P. Moreau, D. Espinouse, A. Schmidt, L. Kammoun, H. Ghesquieres, C. Ferlay, J.O. Bay, S. Lissandre, D. Pérol, M. Michallet & P. Quittet. (2012) A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). European Journal of Cancer 48:5, pages 713-720.
Crossref
Crossref
Daniel Hendler, Shulamith Rizel, Rinat Yerushalmi, Victoria Neiman, Luisa Bonilla, Rony Braunstein, Aaron Sulkes & Salomon M. Stemmer. (2011) Different Schedules of Granulocyte Growth Factor Support for Patients With Breast Cancer Receiving Adjuvant Dose-Dense Chemotherapy. American Journal of Clinical Oncology 34:6, pages 619-624.
Crossref
Crossref
R Pettengell, M Schwenkglenks, P Bacon, S Lawrinson & U Duehrsen. (2011) Pegfilgrastim primary prophylaxis in patients with non‐Hodgkin lymphoma: results from an integrated analysis. Hematological Oncology 29:4, pages 177-184.
Crossref
Crossref
Hong Zhao, Lee M. Greenberger & Ivan D. Horak. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
627
665
.
Bing-Bing Yang & Anna Kido. (2011) Pharmacokinetics and Pharmacodynamics of Pegfilgrastim. Clinical Pharmacokinetics 50:5, pages 295-306.
Crossref
Crossref
Stephanie A. Gregory, Lee S. Schwartzberg, May Mo, Jorge Sierra & Charles Vogel. (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis. Community Oncology 7:7, pages 297-308.
Crossref
Crossref
J. Randolph Hecht, Madhavan Pillai, Russell Gollard, William Heim, Forrest Swan, Ravi Patel, Lyndah Dreiling, May Mo & Imtiaz Malik. (2010) A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy. Clinical Colorectal Cancer 9:2, pages 95-101.
Crossref
Crossref
William Renwick, Ruth Pettengell & Michael Green. (2009) Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy. BioDrugs 23:3, pages 175-186.
Crossref
Crossref
MaryAnn Foote & George Morstyn. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
569
580
.
Lew M. IacovelliBrandy L. Persson. (2008) Management of Chemotherapy-Induced Neutropenia: Opportunities for Pharmacist Involvement. Hospital Pharmacy 43:6, pages 472-484.
Crossref
Crossref
Alberto Ballestrero, Davide Boy, Roberta Gonella, Maurizio Miglino, Marino Clavio, Valentina Barbero, Alessio Nencioni, Marco Gobbi & Franco Patrone. (2007) Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Annals of Hematology 87:1, pages 49-55.
Crossref
Crossref
Bing‐Bing Yang, Anna Kido & Atsuko Shibata. (2012) Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:10, pages 1387-1393.
Crossref
Crossref
N Piccirillo, S De Matteis, S De Vita, L Laurenti, P Chiusolo, F Sorà, G Reddiconto, G d'Onofrio, G Leone & S Sica. (2007) Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 40:6, pages 579-583.
Crossref
Crossref
Ulrich J. M. Mey, Anna Maier, Ingo G. H. Schmidt-Wolf, Carsten Ziske, Helmut Forstbauer, Gamal-Andre Banat, Michael Reber, John W. Strehl & Marcus Gorschlueter. (2007) Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer 15:7, pages 877-884.
Crossref
Crossref
Riccardo RicottaGiulio CereaIlaria SchiavettoMaria Rosaria MaugeriPaolo PedrazzoliSalvatore Siena. (2006) Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. Future Oncology 2:6, pages 667-676.
Crossref
Crossref
Massimo Martino, Giulia Praticò, Giuseppe Messina, Giuseppe Irrera, Elisabetta Massara, Giuseppe Messina, Giuseppe Console & Pasquale Iacopino. (2006) Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. European Journal of Haematology 77:5, pages 410-415.
Crossref
Crossref
A Nosari, R Cairoli, D Ciapanna, L Gargantini, L Intropido, C Baraté, B Scarpati, L Santoleri, G Nador, L Pezzetti & E Morra. (2006) Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplantation 38:6, pages 413-416.
Crossref
Crossref
Gaëtan Vanstraelen, Pascale Frère, Marie-Christine Ngirabacu, Evelyne Willems, Georges Fillet & Yves Beguin. (2006) Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Experimental Hematology 34:3, pages 382-388.
Crossref
Crossref
Ingmar Bruns, Ulrich Steidl, Ralf Kronenwett, Roland Fenk, Thorsten Graef, Ulrich-Peter Rohr, Frank Neumann, Johannes Fischer, Christof Scheid, Kai Hübel, Rainer Haas & Guido Kobbe. (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:2, pages 180-185.
Crossref
Crossref
Harold J. Burstein, Leroy M. Parker, Aparna Keshaviah, Jennifer Doherty, Ann H. Partridge, Lidia Schapira, Paula D. Ryan, Jerry Younger, Lyndsay N. Harris, Beverly Moy, Steven E. Come, Susan T. Schumer, Craig A. Bunnell, Margaret Haldoupis, Rebecca Gelman & Eric P. Winer. (2005) Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology 23:33, pages 8340-8347.
Crossref
Crossref
Diana Lüftner & Kurt Possinger. (2005) Pegfilgrastim – Rational Drug Design for the Management of Chemotherapy-Induced Neutropenia. Oncology Research and Treatment 28:11, pages 595-602.
Crossref
Crossref
U Steidl, R Fenk, I Bruns, F Neumann, M Kondakci, B Hoyer, T Gräf, U-P Rohr, S Bork, R Kronenwett, R Haas & G Kobbe. (2004) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation 35:1, pages 33-36.
Crossref
Crossref
K. Possinger, A. Schauer, F. Griesinger & A. C. Roever. 2005. The Sentinel Lymph Node Concept. The Sentinel Lymph Node Concept
503
551
.
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:1, pages 35-42.
Crossref
Crossref
. (2004) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 13:2, pages 117-132.
Crossref
Crossref